financetom
Business
financetom
/
Business
/
Why SoFi Technologies Stock Was A Top Performer In June
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why SoFi Technologies Stock Was A Top Performer In June
Jul 1, 2025 12:46 PM

SoFi Technologies Inc ( SOFI ) shares are trading lower Tuesday afternoon, pulling back from Monday’s 52-week peak potentially amid profit-taking

The fintech company's stock surged throughout June, propelled by strategic announcements and bullish growth projections.

What To Know: Last week, SoFi revealed its renewed cryptocurrency ambitions, planning to let members trade assets like Bitcoin and Ethereum later this year. The initiative will also feature crypto-backed loans and international money transfers.

CEO Anthony Noto confirmed blockchain innovations would be integrated across all SoFi business lines, from investing to borrowing and payments.

This move builds on strong momentum from earlier in June when executives reaffirmed aggressive growth targets. At the William Blair Growth Stock Conference, CFO Chris Lapointe projected adjusted net revenue will exceed $3 billion by 2025, with annual growth surpassing 25% through 2026.

Analyst Ratings: While Wall Street analysts have presented a range of views on SoFi Technologies ( SOFI ) in recent months, the overall sentiment leans towards a constructive outlook.

Recent activity highlights this mixed but generally positive perspective. On June 2nd, Truist Securities initiated its coverage with a Hold rating, setting a price target of $14 per share.

This followed a series of analyst updates on April 30th. Barclays maintained its Equal-Weight rating while increasing its price target to $12 from $11. On the same day, UBS reiterated a Neutral stance but lifted its price target to a range of $14.00 to $15.50.

In contrast, Needham expressed a more bullish view, reiterating a Buy rating and a $20 price target, suggesting a significant potential upside from current levels.

Price Action: According to data from Benzinga Pro, SOFI shares are trading lower by 2.9% to $17.68 Tuesday afternoon. The stock has a 52-week high of $18.92 and a 52-week low of $6.01.

Read Also: Cathie Wood’s Ark Invest Continues To Offload Coinbase, Bets Big On SoFi Technologies

How To Buy SOFI Stock

By now you're likely curious about how to participate in the market for SoFi Technologies ( SOFI ) – be it to purchase shares, or even attempt to bet against the company.

Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy “fractional shares,” which allows you to own portions of stock without buying an entire share.

In the case of SoFi Technologies ( SOFI ), which is trading at $17.68 as of publishing time, $100 would buy you 5.66 shares of stock.

If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to “go short” a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.

Image: Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Editas Medicine Says Its Gene Editing Potential Treatment for Sickle-Cell Disease Found Well-Tolerated in Phase 1/2 Trial
Editas Medicine Says Its Gene Editing Potential Treatment for Sickle-Cell Disease Found Well-Tolerated in Phase 1/2 Trial
Jun 14, 2024
05:10 AM EDT, 06/14/2024 (MT Newswires) -- Editas Medicine ( EDIT ) said Friday that new data in a phase 1/2 trial of its gene-editing cell therapy medicine renizgamglogene autogedtemcel showed its was well-tolerated and had a safety profile consistent with other treatments of patients with sickle-cell disease, a blood disorder. The company describes the drug, also called reni-cel, as...
Vertex Pharmaceuticals Says Gene-Editing Therapy Demonstrates Clinical Benefits in Genetic Disease Trials
Vertex Pharmaceuticals Says Gene-Editing Therapy Demonstrates Clinical Benefits in Genetic Disease Trials
Jun 14, 2024
05:13 AM EDT, 06/14/2024 (MT Newswires) -- Vertex Pharmaceuticals ( VRTX ) said Friday its Casgevy gene-editing therapy demonstrated clinical benefits in trials in sickle cell disease and transfusion-dependent beta thalassemia. In sickle cell disease, about 92% of evaluable patients were shown to be free from vaso-occlusive crises, or VOCs, for at least 12 months, while 97% of patients with...
Zapp Electric Vehicles Signs Distribution Contract in India
Zapp Electric Vehicles Signs Distribution Contract in India
Jun 14, 2024
05:00 AM EDT, 06/14/2024 (MT Newswires) -- Zapp Electric Vehicles Group ( ZAPP ) said it intends to appoint Bounce Electric 1 Private Limited as its contract manufacturing partner for the sales of the i300 in India. The British electric vehicle brand signed a memorandum of understanding to this effect. It said on Thursday Bounce operates a domestic vehicle assembly...
Cabaletta Bio Says Autoimmune Disease Therapy Showed Promise in Early Results
Cabaletta Bio Says Autoimmune Disease Therapy Showed Promise in Early Results
Jun 14, 2024
05:02 AM EDT, 06/14/2024 (MT Newswires) -- Cabaletta Bio ( CABA ) said Friday initial data from each of the first two patients dosed with its CABA-201 experimental therapy to treat autoimmune disease in early-to-mid-stage studies showed the treatment was well-tolerated and potentially effective in resetting the immune system. The company said the data showed no serious adverse events, cytokine...
Copyright 2023-2026 - www.financetom.com All Rights Reserved